Effect of Implantation and Fixation of Mirena in the Treatment of Adenomyosis and its Influence on Serum Inflammatory Factors.
Leilei. Gong G; Di. Xin X; Na. Li L; Rong. Shao S
Key Findings
- Mirena implantation lowered estrogen (E2) levels more than triptorelin
- Pain scores, uterine volume, IL‑8 and TNF‑α were all reduced in the Mirena group
- Quality‑of‑life scores improved and recurrence was 0% with Mirena versus 12% with triptorelin
- Adverse‑event rate was half as high with Mirena (4% vs 8%)
Practical Outcomes
- For women with adenomyosis, using a levonorgestrel‑releasing IUD may provide better symptom control and fewer side effects than systemic triptorelin injections. This suggests that localized hormone delivery can be a safer, more effective strategy for managing hormone‑driven uterine conditions, a point worth noting for anyone experimenting with hormone modulation.
Summary
A study of 100 women with adenomyosis compared a hormone‑releasing IUD (Mirena) placed during surgery to standard post‑op injections of the peptide drug triptorelin. The IUD group had lower estrogen, less pain, smaller uterine size, lower inflammation, better quality of life, fewer side‑effects and no recurrences, while the triptorelin group showed higher rates of pain, inflammation and recurrence.
Abstract
This experiment was carried out to analyze the placement and fixation of Mirena in the treatment of adenomyosis (AM) and its influence on the level of serum inflammatory factors in patients. For this purpose, the subjects of this study were 100 AM patients hospitalized in our hospital from June 2019 to June 2021. They were divided into two groups according to the lottery method (n=50 for each group). The control group was treated with intramuscular triptorelin after the operation, and the observation group was treated with Mirena during the operation. Sex hormone indexes, VAS score, uterine volume, serum inflammatory indexes, the total incidence of adverse reactions, WHOQOL-BREF score and recurrence rate were compared between the two groups. Results showed that in the observation group after treatment E2VAS score and uterine volume were lower, serum IL-8 and TNF-A were lower, the whoqOL-BREf score was higher, and the recurrence rate (0) was lower than that in the control group (12.00%). The total incidence of adr in the observation group (4.00%) was lower than in the control group (8.00%). Then intraoperative placement of Mirena can effectively regulate sex hormone indexes of AM patients, reduce uterine volume, relieve dysmenorrhea symptoms, reduce the inflammatory response, improve quality of life, and reduce recurrence rate, without obvious adverse reactions.
Study Information
pubmed
2022
2022-07-31T00:00:00.000Z
10.14715/cmb/2022.68.7.2
1
23